BAPoma presenting as an incidental scalp papule: case report, literature review, and screening recommendations for BAP1 tumor predisposition syndrome

References

• Soares de Sá BC, de Macedo MP, Torrezan GT, et al. BAP1 tumor predisposition syndrome case report: pathological and clinical aspects of BAP1-inactivated melanocytic tumors (BIMTs), including dermoscopy and confocal microscopy. BMC Cancer. 2019;19(1):1077.
   PubMed Web of Science ®Google Scholar
• Star P, Goodwin A, Kapoor R, et al. Germline BAP1-positive patients: the dilemmas of cancer surveillance and a proposed interdisciplinary consensus monitoring strategy. Eur J Cancer. 2018;92:48–53.
   PubMed Web of Science ®Google Scholar
• Walpole S, Pritchard AL, Cebulla CM, et al. Comprehensive study of the clinical phenotype of germline BAP1 variant-carrying families worldwide. J Natl Cancer Inst. 2018;110(12):1328–1341.
   PubMedGoogle Scholar
• Battaglia A. The importance of multidisciplinary approach in early detection of BAP1 tumor predisposition syndrome: clinical management and risk assessment. Clin Med Insights Oncol. 2014;8:37–47.
   PubMedGoogle Scholar
• Ventii KH, Devi NS, Friedrich KL, et al. BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. Cancer Res. 2008;68(17):6953–6962.
   PubMed Web of Science ®Google Scholar
• Masclef L, Ahmed O, Estavoyer B, et al. Roles and mechanisms of BAP1 deubiquitinase in tumor suppression. Cell Death Differ. 2021;28(2):606–625.
   PubMed Web of Science ®Google Scholar
• Ghosh K, Modi B, James WD, et al. BAP1: case report and insight into a novel tumor suppressor. BMC Dermatol. 2017;17(1):13.
   PubMedGoogle Scholar
• Abdel-Rahman MH, Pilarski R, Cebulla CM, et al. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet. 2011;48(12):856–859.
   PubMed Web of Science ®Google Scholar
• Testa JR, Cheung M, Pei J, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011;43(10):1022–1025.
   PubMed Web of Science ®Google Scholar
• Wiesner T, Obenauf AC, Murali R, et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet. 2011;43(10):1018–1021.
   PubMed Web of Science ®Google Scholar
• Luchini C, Veronese N, Yachida S, et al. Different prognostic roles of tumor suppressor gene BAPI in cancer: a systematic review with meta-analysis. Genes Chromosomes Cancer. 2016;55(10):741–749.
   PubMed Web of Science ®Google Scholar
• Zhang AJ, Rush PS, Tsao H, et al. BRCA1-associated protein (BAP1)-inactivated melanocytic tumors. J Cutan Pathol. 2019;46(12):965–972.
   PubMed Web of Science ®Google Scholar
• Soura E, Eliades PJ, Shannon K, et al. Hereditary melanoma: update on syndromes and management. J Am Acad Dermatol. 2016;74(3):395–420.
   PubMed Web of Science ®Google Scholar
• Pilarski R, Carlo M, Cebulla C, et al. BAP1 tumor predisposition syndrome. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews^®. Seattle (WA): University of Washington; 2016.
   Google Scholar
• Cabaret O, Perron E, Bressac-de Paillerets B, et al. Occurrence of BAP1 germline mutations in cutaneous melanocytic tumors with loss of BAP1-expression: a pilot study. Genes Chromosomes Cancer. 2017;56(9):691–694.
   PubMed Web of Science ®Google Scholar
• Carbone M, Ferris LK, Baumann F, et al. BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med. 2012;10:179.
   PubMed Web of Science ®Google Scholar
• Blokx WA, Rabold K, Bovenschen HJ, et al. NRAS-mutated melanocytic BAP1-associated intradermal tumor (MBAIT): a case report. Virchows Arch. 2015;466(1):117–121.
   PubMed Web of Science ®Google Scholar
• Hillen LM, Van den Oord J, Geybels MS, et al. Genomic landscape of spitzoid neoplasms impacting patient management. Front Med (Lausanne). 2018;5:344.
   PubMed Web of Science ®Google Scholar
• Apalla Z, Nikolaidou C, Lallas A, et al. Clinicopathologically problematic melanocytic tumors: a case-based review. Dermatol Pract Concept. 2018;8(4):306–313.
   PubMedGoogle Scholar
• Maher ER. Hereditary renal cell carcinoma syndromes: diagnosis, surveillance and management. World J Urol. 2018;36(12):1891–1898.
   PubMed Web of Science ®Google Scholar
• Rai K, Pilarski R, Cebulla CM, et al. Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases. Clin Genet. 2016;89(3):285–294.
   PubMed Web of Science ®Google Scholar
• Pilarski R, Cebulla CM, Massengill JB, et al. Expanding the clinical phenotype of hereditary BAP1 cancer predisposition syndrome, reporting three new cases. Genes Chromosomes Cancer. 2014;53(2):177–182.
   PubMed Web of Science ®Google Scholar
• Ewens KG, Lalonde E, Richards-Yutz J, et al. Comparison of germline versus somatic mutations for risk of metastasis in uveal melanoma. BMC Cancer. 2018;18(1):1172.
   PubMedGoogle Scholar
• Jager MJ, Shields CL, Cebulla CM, et al. Uveal melanoma. Nat Rev Dis Primers. 2020;6(1):24.
   PubMed Web of Science ®Google Scholar
• Damato EM, Damato BE. Detection and time to diagnosis of uveal melanoma in the United Kingdom: and evaluation of 2384 patients. Ophthalmology. 2012;119(8):1582–1589.
   PubMed Web of Science ®Google Scholar
• Shields CL, Furuta M, Thangappan A, et al. Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch Ophthalmol. 2009;127(8):989–998.
   PubMedGoogle Scholar
• Hartman RI, Lin JY. Cutaneous melanoma – a review in detection, staging, and management. Hematol Oncol Clin North Am. 2019;33(1):25–38.
   PubMed Web of Science ®Google Scholar
• Bibbins-Domingo K, Grossman DC, Curry SJ, et al. Screening for skin cancer: US Preventive Services Task Force Statement. JAMA. 2016;316(4):429–435.
   PubMed Web of Science ®Google Scholar
• Creaney J, Robinson BWS. Malignant mesothelioma biomarkers: from discovery to use in clinical practice for diagnosis, monitoring, screening and treatment. Chest. 2017;152(1):143–149.
   PubMed Web of Science ®Google Scholar
• Popova T, Hebert L, Jacquemin V, et al. Germline BAP1 mutations predispose to renal cell carcinomas. Am J Hum Genet. 2013;92(6):974–980.
   PubMed Web of Science ®Google Scholar
• Joseph RW, Kapur P, Serie DJ, et al. Clear cell renal cell carcinoma subtypes identified by BAP1 and PBRM1 expression. J Urol. 2016;195(1):180–187.
   PubMed Web of Science ®Google Scholar